业绩符合预期，公司门诊量快速增长

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for its stock performance in the near term [1][4]. Core Insights - The company achieved a revenue of 20.37 billion yuan in 2023, representing a year-over-year growth of 26.43%. The net profit attributable to shareholders was 3.36 billion yuan, up by 33.07% [2][3]. - The company's outpatient visits exceeded 15 million in 2023, marking a 34.26% increase, while surgical procedures surpassed 1.1 million, growing by 35.95% [3][5]. - The company is expanding its regional market presence through its "1+8+N" strategy, enhancing its network of eye care centers across major cities [5][6]. - The gross margin for 2023 was 50.79%, with a net margin of 17.95%, reflecting improved management efficiency and scale effects [5][6]. Financial Summary - The company reported a diluted EPS of 0.36 yuan in 2023, with projections of 0.45 yuan for 2024 and 0.58 yuan for 2025 [2][6]. - The P/E ratio is projected to decrease from 34.0 in 2023 to 27.3 in 2024, indicating a more attractive valuation as earnings grow [2][6]. - The total assets of the company are expected to increase from 30.19 billion yuan in 2023 to 46.35 billion yuan by 2026 [6]. Market Position - The company is positioned as a leading player in the ophthalmology medical service sector in China, benefiting from a large patient population and a growing demand for eye care services [4][5]. - The report anticipates continued high growth in the ophthalmology sector, supported by the company's established expansion model and market leadership [5][6].